Genetic and Pathological Studies of Cancers Associated with BRCA1/BRCA2

This observational study aims to better understand breast, ovarian, fallopian tube, peritoneal, and endometrial cancers, especially in people at high genetic risk. Researchers will study how these cancers develop and how environmental factors might play a role. They will also evaluate how well treatments work for these diseases. You may be eligible if you are a woman aged 18 or older with a high risk of developing breast or ovarian cancer due to a known genetic change (mutation) in genes like BRCA1/2, PTEN, CDH1, or TP53, or if you have a strong family history of these cancers without a known genetic mutation. The study is also looking for women with sporadic breast cancer (no family history) and healthy volunteers without a personal or family history of cancer to serve as comparison groups. This study is currently unclear on its recruitment status.

Study design
This is an observational study with a planned enrollment of 3300 participants. It aims to compare outcomes between different groups of women.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01034033

Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples

Recruiting
Not specifiedAges 18+Observational
Stanford University
~3,300 participants
Updated 2026-05-18 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring

A primary outcome measure isn't published for this study.

Breast Cancer
Ovarian Cancer
Gynecologic Cancers
Ovarian/Peritoneal/Fallopian Cancer
1 sites across 1 states
California1
  • James M Ford · PRINCIPAL_INVESTIGATOR · Stanford University

Opens a ready-to-send draft in your own email app — review before sending.